ResMed (RMD) Earnings Date & Reports

Key Takeaways

• ResMed is scheduled to report fiscal Q4 2026 results on August 6, 2026, after the market closes.
• Analysts expect adjusted earnings per share (EPS) of $2.90, up 13.7% from $2.55 in the same quarter last year.
• Consensus revenue stands at approximately $1.46 billion, representing an 8.4% year-over-year increase.
• The company has beaten Wall Street EPS estimates in each of the past four quarters, most recently delivering $2.86 against a $2.79 consensus in fiscal Q3 2026.
• RMD shares have declined roughly 18.7% over the past 52 weeks, significantly underperforming the broader market and healthcare sector.
• Investor focus will center on device demand trends, gross margin trajectory, the Noctrix Health acquisition impact, and the evolving relationship between GLP-1 weight-loss drugs and sleep apnea therapy adoption.

Earnings Context and Why It Matters

ResMed Inc. (NYSE: RMD), the San Diego-based global leader in cloud-connected sleep apnea and respiratory care devices, enters its fiscal fourth-quarter 2026 earnings report at a critical juncture. The stock has been under considerable pressure despite consistently strong operational execution, creating a sharp disconnect between financial performance and market sentiment. With a current market capitalization of approximately $29.9 billion and shares trading near $208, well below the 52-week high of $293.81, this earnings release represents an opportunity for management to reinforce the growth narrative. Investors will be closely evaluating whether sustained demand for continuous positive airway pressure (CPAP) devices, masks, and the company's digital health ecosystem can reignite confidence after months of underperformance relative to the S&P 500.

Earnings Expectations

Wall Street consensus, drawn from multiple analyst surveys, projects ResMed will deliver adjusted EPS of $2.90 for the fiscal fourth quarter ending June 30, 2026. That would mark a 13.7% increase over the $2.55 reported in the year-ago period. Revenue is expected to reach roughly $1.46 billion, an 8.4% gain compared with $1.348 billion in fiscal Q4 2025. For the full fiscal year 2026, analysts forecast adjusted EPS of approximately $11.13, up 16.5% from $9.55 in fiscal 2025.

ResMed has a strong track record of surpassing estimates: in fiscal Q3 2026, the company posted adjusted EPS of $2.86 on revenue of $1.43 billion, beating consensus by $0.07 per share. Despite that beat, the stock dropped 4.1% the following day, underscoring the elevated bar investors have set. This quarter, attention will also turn to the recently closed $340 million acquisition of Noctrix Health, a developer of wearable therapeutics for restless legs syndrome (RLS). Management has indicated the deal will contribute a modest negative impact of approximately $0.02 to non-GAAP EPS (non-GAAP earnings per share, which exclude certain one-time items) in the quarter, and investors will want to hear how integration is progressing.

Key operating metrics to monitor include organic constant-currency revenue growth, which decelerated slightly to 8.6% in last year's Q4, device versus mask sales growth rates across the Americas and international markets, and the Residential Care Software (RCS) segment, which provides SaaS (Software-as-a-Service) platforms for out-of-hospital care providers and grew 6% year-over-year in Q3.

AI Screener

As investors prepare for ResMed's quarterly results, tools that streamline market analysis become especially valuable. Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that enables traders and investors to filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, performance metrics, and AI-driven signals. The screener is designed to help users identify trade ideas, breakout candidates, trending stocks, and emerging market opportunities more efficiently than traditional manual screening methods. For those tracking the medical device and digital health space ahead of earnings season, the AI Screener offers a data-driven way to scan for related opportunities across the broader healthcare landscape.

Market Reaction and Investor Sentiment

Sentiment heading into ResMed's fiscal Q4 2026 report is cautiously optimistic but tempered. The stock's 18.7% decline over the trailing 52-week period contrasts sharply with the company's double-digit earnings growth, suggesting that macro concerns and sector-specific anxieties — including lingering questions about GLP-1 (glucagon-like peptide-1) receptor agonists, a class of weight-loss and diabetes drugs) impact on sleep apnea treatment demand — have weighed disproportionately on the share price. Analyst consensus rates RMD a "Moderate Buy," with an average price target near $246 to $266, implying potential upside of approximately 19% to 28% from current levels. However, the ratio of Hold ratings has increased in recent months, reflecting a more guarded near-term outlook. ResMed's own research, presented in prior quarters, indicates that patients prescribed both GLP-1 drugs and CPAP therapy are more likely to initiate and adhere to treatment, a dynamic management frames as a demand tailwind rather than a threat. Whether the market embraces that thesis may depend on the tone and substance of commentary accompanying the August 6 release.

Forward Outlook and Key Factors to Monitor

Looking beyond the upcoming report, several factors will shape ResMed's trajectory through fiscal 2027 and beyond. Gross margin expansion remains a central pillar of the investment case. The company guided to a gross margin range of 61% to 63% for fiscal 2026, up from 60% in fiscal 2025, driven by manufacturing efficiencies, favorable product mix, and supply chain improvements. Management has also outlined a multi-year plan targeting continued margin accretion through 2030, with double-digit basis-point improvements annually. Sustained execution on this front will be essential for converting revenue growth into faster earnings expansion.

The Noctrix Health integration introduces a new growth vector. While the near-term financial contribution is small — roughly $24 million in annualized run-rate revenue — the acquisition expands ResMed's sleep health portfolio beyond respiratory care and into movement disorders, potentially opening a new addressable market over the medium term. Investors will look for early indicators of commercial traction and distribution synergies.

On the competitive and regulatory front, the broader conversation around GLP-1 drugs and their intersection with sleep apnea treatment continues to evolve. ResMed's real-world evidence analyses, which span patient cohorts of over 1.7 million individuals, suggest that GLP-1 users who also require CPAP therapy demonstrate higher resupply compliance rates and are more likely to initiate treatment. How management updates and communicates these data points could influence the market's perception of long-term demand durability.

Finally, capital allocation strategy bears watching. ResMed increased its quarterly share repurchase target to $150 million, up from $100 million previously, and maintains a $0.60 per-share quarterly dividend. With approximately $1.66 billion in cash and equivalents on the balance sheet as of March 31, 2026, the company retains ample flexibility for organic investment, M&A (mergers and acquisitions), and shareholder returns, all of which factor into the forward outlook.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations